Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

While the medications may reduce diet, the best results will be achieved by building healthy habits alongside the drugs.

Results from the Phase II C-144-01 trial showed that a single infusion of Amtagvi demonstrated a 31.4% objective response ...

Many Americans struggle with being overweight, social stigmas still prevent people from talking to doctors and seeking ...

Skin cancer is often overlooked by many Americans, who are at elevated risk for being over exposed to the sun in the summer ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Approval was based on results from the Phase III ARANOTE trial, in which Nubeqa demonstrated a 46% reduction in the risk of ...

Approval was based on data from the Phase III NextCOVE trial, which demonstrated that mNEXSPIKE met non-inferiority criteria ...

Poor investigator site selection remains a significant driver of spiraling costs and inefficiencies in clinical development.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good ...